Amylin, Lilly and Alkermes resubmit Bydureon with FDA
This article was originally published in Scrip
Executive Summary
Amylin, Lilly and Alkermes have resubmitted their antidiabetic Bydureon (extended-release exenatide), replying to a complete response letter issued by the US FDA last month.